Lake Street initiated coverage on PaySign with a new price target
$PAYS
Business Services
Consumer Discretionary
Lake Street initiated coverage of PaySign with a rating of Buy and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $6.00 | Buy | Lake Street |
| 3/30/2022 | $4.00 | Mkt Perform | Barrington Research |
| 3/24/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 8/20/2021 | $3.50 | Neutral → Buy | DA Davidson |
| 8/19/2021 | Neutral → Buy | DA Davidson | |
| 8/12/2021 | $3.50 → $3.75 | Neutral → Buy | Ladenburg Thalmann |
8-K - Paysign, Inc. (0001496443) (Filer)
10-Q - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma
For the Full-Year Full-year 2024 total revenues of $58.38 million, up 23.5% from full-year 2023 Full-year 2024 net income of $3.82 million, or diluted earnings per share of $0.07, versus net income of $6.46 million, or diluted earnings per share of $0.12 for full-year 2023 Full-year 2024 Adjusted EBITDA of $9.62 million, up 43.3% from $6.71 million a year ago, while diluted Adjusted EBITDA per share was $0.17 versus $0.12 for full-year 20231 Total plasma center count increased by 16 during 2024, exiting the year with 480 centers, contributing to a 4.6% increase in plasma revenue versus the same period last year Added 33 net patient affordability programs during 2024, exiting the y
Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per share was $0.04 versus $0.02 for second quarter 20231 Total plasma center count increased by eight net new centers during second quarter 2024, exiting the quarter with 477 centers, contributing to a 12.6% increase in plasma revenue versus the same period last year Adde
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
Paysign Strengthens Leadership in Technology for Plasma and Pharmaceutical Industries Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has acquired the assets of Gamma Innovation LLC (Gamma), significantly enhancing Paysign's capabilities in plasma donor and pharmaceutical patient engagement technologies. As part of this strategic acquisition, Paysign has appointed Michael Ngo, former Managing Member of Gamma, as its Chief Innovation Officer. "This acquisition represents an exciting milestone for Paysign as we accelerate our growth strategy and expand our
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
Lake Street initiated coverage of PaySign with a rating of Buy and set a new price target of $6.00
Barrington Research initiated coverage of PaySign with a rating of Mkt Perform and set a new price target of $4.00
Ladenburg Thalmann downgraded PaySign from Buy to Neutral
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced its CFO, Jeff Baker, will be attending and presenting at the MicroCap Rodeo Spring Conference in New York City on Wednesday, June 4, 2025. The presentation will be at 3:00 p.m. Eastern time on Wednesday, June 4, and will be webcast live. Interested parties can register to watch the virtual presentation. Management will also be available for one-on-one meetings with approved investors. Investors interested in attending may visit the event website for more information and to pre-register. Abo
First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, will discuss first quarter 2025 earnings at 5:00 p.m. ET on Thursday, May 8, 2025. Participant details are as follows: U.S. dial-in: 800.579.2543 International dial-in: +1.785.424.1789 Conference ID: PAYSIGN Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13753463 The replay will be available until August 8, 2025. To register as a financial professional in order to ask questions during the call, please email [email protected] no later than 5:00 p.m. ET on Friday, May 2, 2025.